Upload
lorenzo-alonso
View
513
Download
1
Tags:
Embed Size (px)
DESCRIPTION
Concepts about bases for the treatment of uveal melnoma and some uncommon location of cutaneous melanoma
Citation preview
Uncommon locations for melanoma and uveal melanoma
2014
Lorenzo AlonsoMedical Oncology
www.foro-osler.com
Please, could you try to figure out some melanoma locations beyond the skin and subcutaneous area?
Sinus
intracardiac
Bronchial mucosa
Small bowel metastases
Genital/anal
subungueal
Toes/ sole
gingiva
Cardiac metastases from melanoma
Right atrium is the most common site.
Clinical scenario
• Melanoma, anemia, abdominal lump
Metastases to small bowel: usually can be resected
Uveal melanoma: pathophysiology
Location % 5-year mts. %10-year mts
Iris 4% 7%
Ciliary body 19% 33%Choroides 15% 25%
Predrag Jovanovic et al.Int J Clin Exp Pathol 2013;6(7):1230-1244
Conjuntival melanoma is related more with its cutaneous counterpart
Ocular melanoma: pathophysiology
Liver: 93% mts Lung: 24% mts.
WHY?Bones: 16% mts
Local treatment
Radiotherapy (plaque) and surgery (enucleation) achieve the same outcome…but not without harm
Uveal melanoma prognosis
Class 1: low grade tumors with low metastatic risk
Class 2: high grade tumors with metastatic risk chracterized by down-regulation of genes on chromosome 3 and up-regulation of genes on chromosome 8q.
Monosomy of chromosome 3 is the most frequent chromosome aberration in uveal melanoma (50%)
BAP1: BCRA-1 associated protein-1 and metastatic development of uveal melanoma
The gene encoding BAP-1 is located on chromosome 3p21.1 and is mutated in 80% of metastatic uveal melanoma. BAP-1 is a enzyme that forms part of a tumor-suppressor complex. BAP-1 mutation is associated to metastatic behaviour
Uveal melanomaTreatment options
• Ipilimumab
• Chemotherapy: nanoparticles(taxanes)
• MAPK pathway: MEK
• Protein kinase C (PKC)
Outcome after compassionate use (USA, Italy):1-year overall survival over 30%.More common dose: 3 mg/KgMedian overall survival 6 months (Italian use)Toxicity experience and response similar to cutaneous
Ipilimumab in metastatic uveal melanoma
Uveal melanoma: rational for treatment
GNAQ and GNA11 are mutated in a mutually exclusive pattern (83% uveal): these mutations are implicated in the stimulus of MAPK pathway via MEK.
GNAQ/GNA11 signals also via PLC(phospholipase C) and PKC (protein kinase C), enzymes implicated in proliferation, invasion,apoptosis via ERK
Cancer Letters 2006;235:1-10
Therapeutic targets
• MEK inhibitors: (no response in wild-type GNAQ/GNA11)– Selumetinib compared with temozolamide; 9 weeks benefit for
selumetinib for PFS– MEK162
• PAK inhibitors: sotrastaurin (AEB071)/ enzastaurin.– G1 cell cycle arrest– Inhibition of PKC in GNAQ-mutant resulted in the inhibition of the
MAPK pathway.
A combination of a MEK and proteinkinase inhibitor could be a perfect therapeutic combination
Conclusions
• 1. Metastases from melanoma can spread to almost every anatomical location.
• 2. Uveal melanoma is the most common primary malignancy of the eye
• 3. GNAQ and GNA11 are mutated in 80% of uveal melanoma in a mutually exclusive pattern
• 4. Ipilimumab achieves a 30% survival in the first year in uveal melanoma
• 5. MEK inhibitors and PAK inhibitors are key for developing targeted therapies.